• Topbanner

    Management and Board of Directors


Management


Frans Wuite Frans Wuite, MD, MBA

CEO


More info

Frans Wuite has more than 25 years pharmaceutical industry experience encompassing leadership roles in start-ups through to large, international companies. Prior to joining Acesion, Wuite led Oncos Therapeutics, a clinical stage cancer immunotherapy company which was successfully merged with Targovax in 2015. At Oncos he spearheaded fund raising and business development initiatives in the US and Europe. Wuite also pioneered the commercial development and launch of Amgen's anaemia therapy, Aranesp in Europe, which rapidly became the company's biggest product. He also gained early stage clinical development experience at Warren & Araim Pharmaceuticals in the US. Wuite is a board director of Healthcap VII GP S.A. and Herantis Pharma Ltd (HRTIS).


Ulrik Sørensen Ulrik Sørensen, PhD

COO


More info

Dr. Ulrik Sørensen is a co-founder of Acesion Pharma and from 2011-2016 led the company as CEO, successfully raising funding from Danish and international investors, including Novo A/S, Broadview Ventures (US) and Wellcome Trust (UK), the latter as an SDDI Award in 2013 and a Translational Award in 2016. Ulrik Sørensen has 15+ years of experience from pharma and biotech and holds a PhD in medicinal chemistry and a management degree in organization and strategic management from Copenhagen Business School. He has international research experience from the UK, US and Switzerland and was from 2002 to 2012 employed at NeuroSearch where he held positions as Head of Medicinal Chemistry and Project Director. He was involved in several of the discovery programs and working across strategic collaborations between biotech and big pharma companies. In particular, he led the SK channel inhibitor program that later formed the basis for Acesion Pharma.


Morten Grunnet Morten Grunnet, PhD, Dr. Scient

CSO


More info

Morten Grunnet, PhD, DrSc, is co-founder, board member and CSO at Acesion Pharma. Morten Grunnet brings +15 years of drug discovery experience from biotech at director level. He also has experience from big pharma in combination with a solid academic background as full professor and +100 publications. He has lead cross-disciplinary teams for a number of pre-clinical drug discovery projects within CNS and the cardiovascular field. Some of these projects have been strategic collaborations between biotech and big pharma companies. His special interest is on ion channels research in excitable tissues.


Nils Edvardsson Dr. Nils Edvardsson, MD

CMO


More info

Nils Edvardsson is a clinical cardiologist and has worked as Chief cardiologist, arrhythmia section, at Sahlgrenska University Hospital. In addition to that he was a full-time advisor to AstraZeneca and has served as member of numerous advisory and steering commitees on anti-arrhythmic drugs.


Jakob Dynnes Hansen Jakob Dynnes Hansen, MSc (Econ), MBA

CFO


More info

Jakob Dynnes Hansen has more than 25 years of combined experience from biotech and financing. Prior to joining Acesion, he was the CFO for more than 9 years at Evolva, a Swiss public biotech company. At Evolva, he played a key role in the company’s listing in 2009 and several subsequent financings. Previously, he was CFO at two Danish biotech companies, Nuevolution and Zealand Pharma. Before moving into biotech, Mr Hansen spent nine years as senior member of the Corporate Finance Team at Unibank (now Nordea). Prior to Unibank, Jakob was Head of Market Research at Novo Nordisk and he has worked for the United Nations (UNIDO) in Indonesia. Jakob holds an MSc in Economics from the University of Copenhagen and an MBA from INSEAD.


Christina Sylvest Christina Sylvest M.Sc. (Pharm)

SVP Acute Cardioversion


More info

Christina Sylvest has more than 20 years experience of clinical operations and project management leading global and local Phase I-IV clinical programmes. Prior to joining Acesion, she was responsible for Veloxis Pharmaceuticals A/S (previously Life Cycle Pharma A/S) Phase I-IV clinical operational activities both in Europe and in the US. Prior to that, Christina Sylvest worked in various management roles in clinical development at Rheoscience A/S, Novo Nordisk A/S and Ferring Pharmaceuticals A/S.


Breian Knudsen Breian Knudsen M.Sc. (Pharm)

VP CMC


More info

Breian Knudsen has extensive experience in developing and managing the manufacture of drug substance and drug product at various companies including Leo Pharma, Ferrosan, Novo Nordisk, LifeCycle Pharma and Veloxis Pharmaceuticals. Before joining Acesion Pharmaceuticals, he was Vice President Technical Operations at Veloxis being responsible for supplying the company and its business partners with drug products including clinical trial materials and commercial product manufactured according to GMP. Breian Knudsen has a Master of Science degree in Pharmacy from the Royal Danish School of Pharmacy.



Board of Directors


Ingelise Saunders Ingelise Saunders

Chairman of the Board


More info

Ingelise Saunders has more than 35 years of experience in the biotech and pharmaceutical industry. Until September 2013 she was CEO of the Swedish life science investment company SLS Invest AB. Prior to that she was CEO in three privately owned Danish Biotech companies, among these Action Pharma A/S, which was sold to Abbott in 2012. Prior experience includes 16 years at Novo Nordisk A/S in a number of Executive Management positions both in Denmark and in the UK. Apart from being Chairman of the Board of Acesion Pharma Ingelise Saunders is today a Director of the Board of Leo Pharma A/S, Chairman of the Board of MinervaX ApS and CEO of Meta-IQ.


Stephan Christgau Stephan Christgau, PhD

Investment Director, Novo Seeds


More info

Stephan Christgau, PhD joined Novo A/S in September 2007 as Investment Director of Novo Seeds.

Prior to joining Novo Seeds, Dr. Christgau was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. Previously, Dr. Christgau has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.

Dr. Christgau is the author of more than 60 scientific publications and inventor on more than 30 patent families.


Paul Goldenheim Dr. Paul Goldenheim, MD

 


More info

Dr. Paul Goldenheim is a Board Member representing SEED Capital. He is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies. He has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. Dr. Goldenheim also serves on the board of directors of The Big Apple Circus. He received his A.B. from Harvard College magna cum laude with highest honors in biochemical sciences and his M.D. from Harvard Medical School.


Lars Gredsted Lars Gredsted, PhD

Senior Business Analyst, Wellcome Trust


More info

Lars Gredsted is a Board Member of Acesion Pharma representing the Wellcome Trust. Lars is a Senior Business Analyst and joined the Wellcome Trust in 2010. He previously worked with in-licensing of early stage research projects at Union Life Sciences in Oxford. Lars has also worked as management consultant with the Boston Consulting Group, where he worked with marketing strategies for companies in the life science and industrial biotech areas. Lars gained his PhD from the European Molecular Biology Laboratory (EMBL)/Heidelberg University and subsequently worked as a postdoc at EMBL in Heidelberg and at the Biotech Research and Innovation Center (BRIC) in Copenhagen. In addition to his PhD, Lars holds an MPhil in Bioscience Enterprise from Cambridge University and a Master of Biochemistry from the University of Copenhagen.


Morten Grunnet Morten Grunnet, PhD, Dr. Scient

CSO


More info

Morten Grunnet, PhD, DrSc, is co-founder, board member and CSO at Acesion Pharma. Morten Grunnet brings +15 years of drug discovery experience from biotech at director level. He also has experience from big pharma in combination with a solid academic background as full professor and +100 publications. He has lead cross-disciplinary teams for a number of pre-clinical drug discovery projects within CNS and the cardiovascular field. Some of these projects have been strategic collaborations between biotech and big pharma companies. His special interest is on ion channels research in excitable tissues.


Christopher De Souza Christopher De Souza, PhD

Director, Broadview Ventures


More info

Christopher De Souza is a Director at Broadview Ventures in Boston and represents the fund as an Observer of the Board of Acesion Pharma. He started his pharmaceutical career at Novartis as senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances. After Novartis, Christopher was VP of Business Development at SkyePharma US and also founded a business development consulting practice. He received an MBA from Rutgers University and a PhD in physiology from Louisiana State University. He completed his post-doctoral training at "The Upjohn Company" and the Joslin Diabetes Center/Harvard Medical School.